Artal Group S.A. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001053906

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedConsumer TiltHigh Turnover how tags are computed

Q4 2023 · 92 positions · Total reported value $2.93B · Top-10 concentration 77.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2023 13F filing, Artal Group S.A. disclosed 92 equity positions with a combined reported value of $2.93B. The filing implies a focused portfolio: its ten largest positions account for 77.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Consumer Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were CAVA ($1.38B), SRRK ($211.68M), LXRX ($179.86M). By sector, the heaviest allocations are Consumer Discretionary 47.8%, Health Care 36.4%. Versus the prior quarter, allocation shifted toward Health Care (+3.9pp), Consumer Discretionary (+2.1pp) and away from Other (-5.4pp).

Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q4 2023 were ARGX ($44.28M), KRRO ($20.06M), PRTA ($18.22M).

Of the 8 positions fully exited versus the prior quarter, the largest were IMGN ($24.00M), VTYX ($14.07M), RYZB ($12.33M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • ARGX Argenx S.E. · $44.28M
  • KRRO KORRO BIO INC · $20.06M
  • PRTA PROTHENA CORP PLC · $18.22M
  • LXEO LEXEO THERAPEUTICS INC · $8.10M
  • CNTA CENTESSA PHARMACEUTICALS PLC · $8.06M
  • CBAY CYMABAY THERAPEUTICS INC · $7.17M
  • PDD PDD HOLDINGS INC · $4.75M
  • GPCR STRUCTURE THERAPEUTICS INC · $3.53M

Fully Exited (vs previous quarter)

  • IMGN IMMUNOGEN INC · prev qtr: $24.00M
  • VTYX VENTYX BIOSCIENCES INC · prev qtr: $14.07M
  • RYZB RAYZEBIO INC · prev qtr: $12.33M
  • GERN GERON CORP · prev qtr: $11.80M
  • NBTX NANOBIOTIX · prev qtr: $8.75M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $8.73M
  • AUPH AURINIA PHARMACEUTICALS INC · prev qtr: $7.77M
  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $7.75M

Insider Transactions (Form 4)

Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-15 Sell CAVA GROUP, INC. 3,000,000 $90.30 SEC filing
2026-04-30 Opt exercise LEXICON PHARMACEUTICALS, INC. 20,421,735 — SEC filing

All insider transactions →

Fund Profile

Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 2 positions · $931.12M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: CAVA (CAVA GROUP INC) at 54.9%
  • Average position size: $465.56M

Sector Tilt

  • Consumer Discretionary 54.9%
  • Health Care 45.1%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added, 1 reduced

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 36.4%
Technology 0.5%
Financials 0.1%
Other 14.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 32.01M $1.38B 47.01%
47.01%
Hold
2 11.26M $211.68M 7.23%
7.23%
Add
3 117.55M $179.86M 6.15%
6.15%
Hold
4 1.21M $101.38M 3.46%
3.46%
Reduce
5 1.42M $85.08M 2.91%
2.91%
Reduce
6 404.48K $72.95M 2.49%
2.49%
Hold
7 2.53M $64.43M 2.20%
2.20%
Add
8 2.14M $61.75M 2.11%
2.11%
Hold
9 1.62M $58.96M 2.02%
2.02%
Reduce
10 3.00M $52.11M 1.78%
1.78%
Add
11 1.70M $48.64M 1.66%
1.66%
Reduce
12 116.39K $44.28M 1.51%
1.51%
New
13 2.55M $43.52M 1.49%
1.49%
Reduce
14 500.00K $29.38M 1.00%
1.00%
Reduce
15 2.03M $28.75M 0.98%
0.98%
Add
16 3.10M $25.77M 0.88%
0.88%
Add
17 1.77M $25.43M 0.87%
0.87%
Reduce
18 3.04M $22.65M 0.77%
0.77%
Add
19 8.59M $20.27M 0.69%
0.69%
Hold
20 418.61K $20.06M 0.69%
0.69%
New
21 2.51M $19.51M 0.67%
0.67%
Add
22 501.36K $18.22M 0.62%
0.62%
New
23 802.90K $17.23M 0.59%
0.59%
Hold
24 1.22M $16.20M 0.55%
0.55%
Add
25 3.01M $15.19M 0.52%
0.52%
Add
26 372.00K $15.07M 0.52%
0.52%
Reduce
27 1.30M $14.83M 0.51%
0.51%
Add
28 15.63M $12.94M 0.44%
0.44%
Hold
29 200.00K $12.53M 0.43%
0.43%
Hold
30 1.00M $11.23M 0.38%
0.38%
Hold
31 300.00K $10.74M 0.37%
0.37%
Reduce
32 4.72M $10.06M 0.34%
0.34%
Hold
33 1.01M $9.66M 0.33%
0.33%
Reduce
34 4.75M $9.21M 0.32%
0.32%
Hold
35 603.43K $8.10M 0.28%
0.28%
New
36 1.01M $8.06M 0.28%
0.28%
New
37 2.50M $8.05M 0.28%
0.28%
Hold
38 303.60K $7.17M 0.24%
0.24%
New
39 68.00K $7.07M 0.24%
0.24%
Reduce
40 3.66M $6.48M 0.22%
0.22%
Hold
41 9.14M $6.30M 0.21%
0.21%
Hold
42 1.81M $6.12M 0.21%
0.21%
Reduce
43 200.00K $6.12M 0.21%
0.21%
Add
44 2.05M $5.75M 0.20%
0.20%
Hold
45 909.22K $5.58M 0.19%
0.19%
Hold
46 2.35M $5.28M 0.18%
0.18%
Reduce
47 700.00K $5.11M 0.17%
0.17%
Hold
48 924.77K $5.01M 0.17%
0.17%
Hold
49 32.50K $4.75M 0.16%
0.16%
New
50 720.72K $4.65M 0.16%
0.16%
Reduce

FAQ

What did Artal Group S.A. buy in 2023-Q4?

In its 2023-Q4 13F filing, Artal Group S.A. reported 92 equity positions worth $2.93B in aggregate; its largest disclosed positions were CAVA ($1.38B), SRRK ($211.68M), LXRX ($179.86M).

How large is Artal Group S.A.'s portfolio?

Artal Group S.A. reported $2.93B of long equity holdings across 92 positions as of 2023-Q4. Top-10 holdings account for 77.4% of reported value.

What is Artal Group S.A.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/artal/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →